These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7117731)

  • 21. Serotonin-induced head shaking behavior in rats does not involve receptors located in the frontal cortex.
    Lucki I; Minugh-Purvis N
    Brain Res; 1987 Sep; 420(2):403-6. PubMed ID: 2960422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of the pharmacology of the quipazine maleate. I. General pharmacology of quipazine maleate].
    Hong E; Phillips BM; Pardo EG
    Gac Med Mex; 1969 Aug; 99(8):741-6. PubMed ID: 5387704
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacological profile of a model for central serotonin receptor activation.
    Matthews WD; Smith CD
    Life Sci; 1980 Apr; 26(17):1397-403. PubMed ID: 6247593
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of TR2515, a serotonin antagonist, on the electrical and behavioral effects induced by stimulation of the olivo-cerebellar system.
    Barragan LA; Galindo-Morales JA; Hong E
    Proc West Pharmacol Soc; 1984; 27():329-32. PubMed ID: 6494172
    [No Abstract]   [Full Text] [Related]  

  • 25. Raphe unit activity in freely moving cats: effects of quipazine.
    Trulson ME; Crisp T; Howell GA
    Neuropharmacology; 1982 Jul; 21(7):681-6. PubMed ID: 7121739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle.
    Cohen ML; Fuller RW; Wiley KS
    J Pharmacol Exp Ther; 1981 Aug; 218(2):421-5. PubMed ID: 7252841
    [No Abstract]   [Full Text] [Related]  

  • 27. Aggressive behavior inhibition by serotonin and quipazine injected into the amygdala in the rat.
    Puciłowski O; Płaźnik A; Kostowski W
    Behav Neural Biol; 1985 Jan; 43(1):58-68. PubMed ID: 4039562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indirect central 5-hydroxytryptaminergic actions of methoxy substituted 2-aminotetralin derivatives.
    Hacksell U; Arvidsson LE; Johansson AM; Nilsson JL; Sanchez D; Lindberg P; Wikström H; Svensson K; Hjorth S; Carlsson A
    Acta Pharm Suec; 1986; 23(2):77-90. PubMed ID: 3739739
    [No Abstract]   [Full Text] [Related]  

  • 29. Behavioral effects of quipazine in the cat.
    Trulson ME; Brandstetter JW; Crisp T; Jacobs BL
    Eur J Pharmacol; 1982 Mar; 78(3):295-305. PubMed ID: 6461558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hematoporphyrin antagonism of the serotoninergic receptor].
    Franzone JS; Cirillo R; Cravanzola C
    Boll Chim Farm; 1978 Apr; 117(4):235-9. PubMed ID: 743371
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduced head-twitch response to quipazine of rats previously treated with methiothepin: possible involvement of dopaminergic system.
    Dall'Olio R; Vaccheri A; Montanaro N
    Pharmacol Biochem Behav; 1985 Jul; 23(1):43-8. PubMed ID: 2994121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quipazine-induced behavior in neonatal rat pups.
    Spear LP; Ristine LA
    Pharmacol Biochem Behav; 1981 Jun; 14(6):831-4. PubMed ID: 7255519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quipazine has a biphasic effect on slow wave sleep and reduces REM sleep rebound in REM sleep deprived rats.
    Zak R; Radulovacki M
    Brain Res Bull; 1982 Mar; 8(3):329-31. PubMed ID: 7093740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms by which quipazine, a putative serotonin receptor agonist, alters brain 5-hydroxyindole metabolism.
    Jacoby JH; Howd RA; Levin MS; Wurtman RJ
    Neuropharmacology; 1976 Sep; 15(9):529-34. PubMed ID: 980228
    [No Abstract]   [Full Text] [Related]  

  • 35. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
    Hinschberger A; Butt S; Lelong V; Boulouard M; Dumuis A; Dauphin F; Bureau R; Pfeiffer B; Renard P; Rault S
    J Med Chem; 2003 Jan; 46(1):138-47. PubMed ID: 12502367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dependence of curare-like activity of derivatives of cyclobutan dicarboxylic acids on the structure of the central part of the molecule].
    Kharkevich DA
    Farmakol Toksikol; 1966; 29(6):715-20. PubMed ID: 6000368
    [No Abstract]   [Full Text] [Related]  

  • 37. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
    Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Head twitches induced by LSD and quipazine: similarities and differences.
    Vetulani J; Bednarczyk B; Reichenberg K; Rokosz A
    Neuropharmacology; 1980 Feb; 19(2):155-8. PubMed ID: 6244515
    [No Abstract]   [Full Text] [Related]  

  • 39. Decrease of food intake by quipazine in the rat: relation to serotoninergic receptor stimulation.
    Samanin R; Bendotti C; Miranda F; Garattini S
    J Pharm Pharmacol; 1977 Jan; 29(1):53-4. PubMed ID: 13187
    [No Abstract]   [Full Text] [Related]  

  • 40. Different behavioral mechanisms underlie tolerance to the anorectic effects of fenfluramine and quipazine.
    Rowland N; Carlton J
    Psychopharmacology (Berl); 1983; 81(2):155-7. PubMed ID: 6415747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.